文献速递炎症性肠病

阿达木单抗与英夫利西单抗在儿童腔内型克罗恩病中的比较:前瞻性多中心队列研究显示结局相当

Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2023-10-03

本研究比较阿达木单抗(ADA)与英夫利西单抗(IFX)作为首个抗TNF药物治疗儿童腔内型克罗恩病(CD)的真实世界有效性。纳入2014至2020年加拿大儿童炎症性肠病网络全国初始队列中开始ADA或IFX的儿童,经倾向性评分匹配后每组147例。1年无激素临床缓解率ADA组92例(63%)与IFX组87例(59%)相似(校正OR 1.4,95%CI 0.9-2.4);ADA组治疗强化频率更低(14% vs 47%,P<0.0001)。

要点

  • 在倾向性评分匹配的儿童CD队列中,ADA与IFX作为首个抗TNF药物1年无激素临床缓解率相似(63% vs 59%)。
  • ADA组治疗强化发生率显著低于IFX组(14% vs 47%,P<0.0001)。
  • 两组抗TNF停药率无显著差异(12% vs 10%;校正HR 1.2,95%CI 0.6-2.2)。

核心结论

  • 儿童CD患者以ADA或IFX作为首个抗TNF药物在1年时均获得良好结局;接受IFX者与临床相似的接受ADA者相比,结局未显著更优。

研究设计与样本

  • 前瞻性多中心队列研究,纳入2014至2020年加拿大儿童炎症性肠病网络全国初始队列中以ADA或IFX作为首个抗TNF药物治疗腔内型CD的儿童;采用多变量logistic回归建模启动ADA的倾向性,并用倾向性评分匹配将IFX治疗儿童与ADA治疗儿童匹配。

主要发现

  • 在147例ADA治疗与147例IFX治疗的倾向性评分匹配队列中,1年无激素临床缓解:ADA组92例(63%)vs IFX组87例(59%)(校正OR 1.4,95%CI 0.9-2.4)。
  • 1年联合无激素临床缓解与C反应蛋白缓解:ADA组75/140例(54%)vs IFX组85/144例(59%)(校正OR 1.0,95%CI 0.6-1.6)。
  • 治疗强化:ADA组21例(14%)vs IFX组69例(47%)(P<0.0001)。
  • 抗TNF停药:ADA组18例(12%)vs IFX组15例(10%)(校正HR 1.2,95%CI 0.6-2.2)。

关键数值与推荐

  • 主要结局为1年无激素临床缓解;次要结局为1年联合无激素临床缓解与C反应蛋白缓解、治疗强化和抗TNF药物持久性。
  • 报告校正了合并免疫调节剂使用的比值比(OR)和风险比(HR)及95%置信区间(CI)。

临床怎么用

  • 原文未据此给出推荐;作者指出以ADA或IFX作为首个抗TNF药物的儿童CD患者1年结局良好,接受IFX者与临床相似的接受ADA者相比结局未显著更优。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study compared real-world effectiveness between adalimumab (ADA) and infliximab (IFX) in children with Crohn's disease (CD). METHODS: Children enrolled into the prospective Canadian Children Inflammatory Bowel Disease Network National Inception Cohort between 2014 and 2020 who commenced ADA or IFX as first antitumor necrosis factor (anti-TNF) agent for luminal CD were included. Multivariate logistic regression modeled the propensity of commencing ADA; propensity score matching was used to match IFX-treated children to ADA-treated children. The primary outcome at 1 year was steroid-free clinical remission (SFCR). Secondary outcomes at 1 year were (i) combined SFCR and C-reactive protein remission, (ii) treatment intensification, and (iii) anti-TNF durability. Odds ratios (ORs) and hazard ratio adjusted for concomitant immunomodulator use with 95% confidence interval (CI) are reported. RESULTS: In the propensity score-matched cohort of 147 ADA-treated and 147 IFX-treated children, 92 (63%) ADA-treated and 87 (59%) IFX-treated children achieved SFCR at 1 year (adjusted OR 1.4, 95% CI 0.9-2.4); 75 of 140 (54%) ADA-treated and 85 of 144 (59%) IFX-treated children achieved combined SFCR and C-reactive protein remission (adjusted OR 1.0, 95% CI 0.6-1.6). ADA-treated children less frequently underwent treatment intensification (21 [14%]) compared with IFX-treated children (69 [47%]) ( P < 0.0001). Discontinuation of anti-TNF occurred in 18 (12%) ADA-treated and 15 (10%) IFX-treated children (adjusted hazard ratio 1.2, 95% CI 0.6-2.2). DISCUSSION: Children with CD achieved favorable outcomes at 1 year with either ADA or IFX as first anti-TNF agents. Those receiving IFX did not have significantly superior outcomes compared with clinically similar children receiving ADA.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. deBruyn JC, Huynh HQ, Griffiths AM, et al. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study. Am J Gastroenterol. 2023. PMID: 37787642. doi:10.14309/ajg.0000000000002552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。